Liminal Biosciences Profit Margin

Liminal Biosciences's profit margin stands at 71.95% as of June 2023. That compares with 9107.96% in the prior-year period — down 99.2% year over year. That is above the Healthcare sector average of 14.41%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Liminal Biosciences reported 71.95% in profit margin versus 9107.96% a year earlier — a 99.2% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Liminal Biosciences sits higher the Healthcare benchmark (14.41%) with a profit margin of 71.95%. That is roughly 399.1% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of 71.95% for Liminal Biosciences means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Liminal Biosciences's profit margin evolved across reporting periods, while the comparison chart places LMNL next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.